817554-69-1

Basic information

• Product Name: L-Proline, 3-methyl-, ethyl ester, (3S)- (9CI)
• Synonyms: L-Proline, 3-methyl-, ethyl ester, (3S)- (9CI)
• CAS NO: 817554-69-1
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.2102
• Product Categories: PYRROLE
• Mol File: 817554-69-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 203.7±33.0 °C(Predicted)
• Appearance: /
• Density: 0.989±0.06 g/cm3(Predicted)
• PKA: 8.26±0.10(Predicted)
• CAS DataBase Reference: L-Proline, 3-methyl-, ethyl ester, (3S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 3-methyl-, ethyl ester, (3S)- (9CI)(817554-69-1)
• EPA Substance Registry System: L-Proline, 3-methyl-, ethyl ester, (3S)- (9CI)(817554-69-1)

Safety Data

• Hazardous Substances Data: 817554-69-1(Hazardous Substances Data)

Upstream product

• 77120-55-9 N-chloro-(2S,3S)-amino-3-methyl-pentanoic acid ethyl ester 
• 921-74-4 L-isoleucine ethyl ester 

Downstream Products

• 10512-89-7 (2S,3S)-3-methylproline 

Relevant articles and documents

Trichodestruxins A-D: Cytotoxic Cyclodepsipeptides from the Endophytic Fungus Trichoderma harzianum

Four new cyclodepsipeptides, trichodestruxins A-D (1-4), together with destruxin E2 chlorohydrin (5) and destruxin A2 (6), were isolated from the plant endophytic fungus Trichoderma harzianum by a bioassay-guided fractionation method. Their planar structures were elucidated on the basis of 1D and 2D NMR and MS/MS spectroscopic analyses. The stereochemical configuration was established by application of the advanced Marfey's method, J-based configuration analysis, Mosher's method, and chemical derivatizations. Trichodestruxin B contains hydroxy acid fragments of the THPA unit, while trichodestruxins A and C contain the β-methylproline moiety. All cyclodepsipeptides displayed cytotoxicity against HT-29, A549, and/or P388 cell lines with IC50 values of 0.7-19.1 μM.

GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.